GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

ENCell Co 456070.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

4,200

+0.84%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About ENCell Co

Its shares trade on KOSDAQ under the ticker 456070.KQ. It has been listed since 23 August 2024. In the fiscal year to 31 December 2025, it reported revenue of ₩5.26bn and a net loss of ₩16.11bn. At that date it held total assets of ₩63.71bn and shareholders' equity of ₩39.40bn.

ENCell Co Ltd is a KR-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Seoul, Seoul. The company went IPO on 2024-08-23. ENCell Co Ltd is a Korea-based company principally engaged in the development and research of new drugs. The firm is principally engaged in the development and research of cell and gene-based biopharmaceuticals. The firm is also engaged in the provision of biopharmaceutical quality testing services. In addition, the Company is engaged in the biopharmaceutical consignment production business.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
23 Aug 2024

Leadership

Pay as last reported

  • Jong Wuk JangChief Executive Officer, Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • ENCell Co Ltd develops new cell and gene-based biopharmaceuticals in Korea.
  • The firm provides essential biopharmaceutical quality testing services to clients.
  • ENCell Co Ltd engages in biopharmaceutical consignment production business operations.

Weaknesses

  • The company is headquartered in Seoul, which may limit local reach.
  • ENCell Co Ltd listed its shares on 23 August 2024 recently.
  • The firm operates in the Life Sciences Tools & Services industry.

Opportunities

  • ENCell Co Ltd can expand its new drug development research efforts.
  • The firm can grow its biopharmaceutical consignment production business segments.
  • ENCell Co Ltd may increase its quality testing service offerings.

Threats

  • ENCell Co Ltd faces competition in the Life Sciences Tools & Services industry.
  • The firm operates in the highly regulated Health Care sector.
  • ENCell Co Ltd is based in Seoul, a competitive market.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.